Harpoon Tx - רווח נקי למניה בארבעת הרבעונים האחרונים HARP

Acquisition by a pharma behemoth neutralized the pre-commercial risks of Harpoon Therapeutics (HARP). The development of T-cell-based targeted therapies against solid tumors reduced pipeline threats, although dependence on external investment and the probability of clinical failures maintained uncertainty. The rolling annual growth rate of net income per share demonstrates the outcome of these processes, where the value of 60.10 determines the status of the parameter.
HARP (Harpoon Therapeutics, Inc.): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Harpoon Therapeutics (HARP) is optimizing costs by utilizing external contract laboratories instead of its own plants. This fabless model is directly reflected in the annual change in net income per share over a rolling period. The metric measures EPS TTM dynamics, allowing for a daily assessment of business efficiency without waiting for quarterly reports. While the positive trend confirms growing profitability, the issuer's hidden risks could trigger sharp drawdowns.